Short Interest in Xenetic Biosciences Inc (NASDAQ:XBIO) Expands By 1,920.0%

Xenetic Biosciences Inc (NASDAQ:XBIOGet Free Report) was the target of a significant growth in short interest in December. As of December 31st, there was short interest totalling 10,100 shares, a growth of 1,920.0% from the December 15th total of 500 shares. Based on an average daily volume of 21,600 shares, the days-to-cover ratio is currently 0.5 days. Currently, 0.8% of the shares of the stock are sold short.

Xenetic Biosciences Stock Up 5.7 %

Shares of NASDAQ XBIO traded up $0.22 during midday trading on Monday, reaching $4.08. The company had a trading volume of 5,304 shares, compared to its average volume of 8,843. The firm’s fifty day moving average price is $4.08 and its 200-day moving average price is $3.99. Xenetic Biosciences has a one year low of $2.78 and a one year high of $5.20. The stock has a market cap of $6.29 million, a PE ratio of -1.53 and a beta of 2.22.

Xenetic Biosciences (NASDAQ:XBIOGet Free Report) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.14). The firm had revenue of $0.61 million for the quarter, compared to analysts’ expectations of $0.75 million. Xenetic Biosciences had a negative net margin of 161.63% and a negative return on equity of 49.51%. As a group, equities research analysts expect that Xenetic Biosciences will post -1.01 EPS for the current year.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “neutral” rating on shares of Xenetic Biosciences in a research report on Thursday, December 5th.

View Our Latest Research Report on XBIO

About Xenetic Biosciences

(Get Free Report)

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.

Recommended Stories

Receive News & Ratings for Xenetic Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenetic Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.